Nicole Lamanna, MD

Dr. Henick is a medical oncologist specializing in the care of patients with malignancies of the aerodigestive tract. As the Director of the HICCC Phase I Unit and Director of Translational Research in Aerodigestive Cancers in Medical Oncology, Dr. Henick’s clinical care and research are aligned to improve the effectiveness of, and limit side effects from, emerging cancer treatments. These efforts entail clinical trials that Dr. Henick has written and leads to study novel therapeutic approaches and to reduce steroid dependence among patients experiencing adverse events from immunotherapy.

Jovana Pavisic, MD in New York, NY is affiliated with Columbia University Irving Medical Center, offering a range of healthcare services. Patients can find family physicians, pediatricians, and surgeons within the network. The facility emphasizes patient care and provides options for virtual visits, ensuring accessibility and convenience. Generated from the website content

Dr. Ryan Moy is an Assistant Professor of Medicine and medical oncologist at Columbia University Irving Medical Center where he specializes in the treatment of gastrointestinal malignancies, with a focus on esophageal and stomach cancers. He received his MD/PhD from the University of Pennsylvania and completed internship and residency training in Internal Medicine at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. He then completed fellowship training in Medical Oncology at Memorial Sloan Kettering Cancer Center and postdoctoral research at The Rockefeller University. Dr. Moy is actively involved in translational research to understand the biological mechanisms that regulate metastasis, the primary driver of mortality in gastrointestinal cancers. He has performed laboratory-based research to define critical genes that promote liver metastasis in colorectal cancer. He is also conducting research to discover key vulnerabilities in esophageal and gastric cancers, with the goal of translating these findings from the lab to develop more effective treatments for patients. As an active member of the gastrointestinal oncology and experimental therapeutics groups, Dr. Moy is involved in developing and leading clinical trials investigating novel targeted and immunotherapy treatments for esophagogastric cancer and other malignancies. His work has been recognized by several awards including a Damon Runyon Cancer Research Foundation Fellow Award and a National Cancer Institute (NCI) K08 Career Development Award. Dr. Moy works as part of a multidisciplinary team with the mission of delivering compassionate and state-of-the-art oncologic care to each patient, using a precision medicine approach to provide innovative and promising treatments.